 SAN DIEGO, Aug. 9, 2021 PRNewswire -- Inhibrx, Inc. Nasdaq: INBX, a biotechnology company with four clinical programs in development, today reported financial results for the second quarter of 2021. Financial Results Cash and Cash Equivalents. 